Form D · Biotechnology
NFlection Therapeutics, Inc.
Boston, MA · CIK 0001694227
Offering snapshot reported Jul 21, 2023 · SEC filing
- Reported sold
- $4M Offering amount: $4M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 7, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 21, 2023 | Initial | $4,000,000 | No comparison | 2 | SEC filing |
| Jun 21, 2022 | Amendment | $20,000,000 | $10,000,000vs Jun 10, 2022 | 2 | SEC filing |
| Jun 10, 2022 | Initial | $10,000,000 | No comparison | 2 | SEC filing |
| Apr 24, 2020 | Amendment | $20,000,000 | $18,600,000vs Jan 17, 2017 | 2 | SEC filing |
| Jan 17, 2017 | Initial | $1,400,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-487531
Source: Form D, filed Jul 21, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark De Souza | Director, Executive |
| Corey Goodman | Director |
| Josh Grass | Director |
| William Hodder | Director, Executive |
| Ketan Patel | Director |
| Christopher Powala | Director |
| Michael Wootton | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
867 Boylston Street, 5 Th Floor #1116
Boston, MA, 02116
Boston, MA, 02116